Evidence map›Paper›PMID 42222354›Full record

ArticleMolecular therapy. Advances2026

Prevalence of pre-existing neutralizing antibodies to AAV5 and AAV8 in patients with Wilson's disease.

Zi-Wei Zheng, Hong Liu, Ling-Yu Guo, Lu-Na Fan, Chuan Liu, Fu-Rong Li, Ran Zhou, Lin Qu, Rou-Min Wang, Wan-Qing Xu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zi-Wei ZhengDepartment of Medical Genetics and Center for Rare Diseases, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Key Laboratory of Rare Diseases for Precision Medicine and Clinical Translation, Hangzhou 310000, China.
Hong LiuSichuan Real & Best Biotech Co., Ltd, Sichuan, Chengdu 610000, China.
Ling-Yu GuoDepartment of Medical Genetics and Center for Rare Diseases, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Key Laboratory of Rare Diseases for Precision Medicine and Clinical Translation, Hangzhou 310000, China.
Lu-Na FanDepartment of Medical Genetics and Center for Rare Diseases, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Key Laboratory of Rare Diseases for Precision Medicine and Clinical Translation, Hangzhou 310000, China.
Chuan LiuDepartment of Medical Genetics and Center for Rare Diseases, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Key Laboratory of Rare Diseases for Precision Medicine and Clinical Translation, Hangzhou 310000, China.
Fu-Rong LiSichuan Real & Best Biotech Co., Ltd, Sichuan, Chengdu 610000, China.
Ran ZhouSichuan Real & Best Biotech Co., Ltd, Sichuan, Chengdu 610000, China.
Lin QuSichuan Real & Best Biotech Co., Ltd, Sichuan, Chengdu 610000, China.
Rou-Min WangDepartment of Medical Genetics and Center for Rare Diseases, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Key Laboratory of Rare Diseases for Precision Medicine and Clinical Translation, Hangzhou 310000, China.
Wan-Qing XuDepartment of Medical Genetics and Center for Rare Diseases, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Key Laboratory of Rare Diseases for Precision Medicine and Clinical Translation, Hangzhou 310000, China.
Guo-Min YangDepartment of Medical Genetics and Center for Rare Diseases, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Key Laboratory of Rare Diseases for Precision Medicine and Clinical Translation, Hangzhou 310000, China.
Biao DongNational Clinical Research Center for Geriatrics and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610000, China.
Yi DongDepartment of Medical Genetics and Center for Rare Diseases, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Key Laboratory of Rare Diseases for Precision Medicine and Clinical Translation, Hangzhou 310000, China.
Zhi-Ying WuDepartment of Medical Genetics and Center for Rare Diseases, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang Key Laboratory of Rare Diseases for Precision Medicine and Clinical Translation, Hangzhou 310000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wilson's disease (WD) is an autosomal recessive copper metabolism disorder. AAV-based gene therapy is promising but hindered by pre-existing neutralizing antibodies (NAbs), with no region-specific data on AAV5 and AAV8 NAbs in WD patients. This study aimed to address this gap. We investigated AAV5 and AAV8 NAb seroprevalence and dynamics in a cohort of Chinese WD patients via a cell-based transduction inhibition assay. Results showed that seroprevalence of AAV8 (58.52%) was higher than that of AAV5 (44.89%), with AAV8 NT50 titers 4.6-fold higher (

Indexed as

adeno-associated virusgene therapyneutralizing antibodiesseroprevalenceWilson’s disease

Identifiers

PMID42222354
PMCPMC13217474

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.